TABLE 2

Individual Characteristics of 23 IBC Patients

Patient no.GradeHR statusHER2 statusTreatmentSUV1ΔSUV1–2ΔSUV1–3Clinical responsePathologic response
13NegNegAnthracycline-based × 625−62.8%−70%PRNon-pCR
23NegNegAnthracycline-based × 4, docetaxel × 43.9−43.6%−41%PRNon-pCR
31PosNegAnthracycline-based × 64.3−72%−72%PRNon-pCR
42PosNegAnthracycline-based × 614−50%−64.3%PRNon-pCR
51PosNegAnthracycline-based × 614−2.1%−88.6%PRNon-pCR
62NegPosAnthracycline-based × 64.9−81.6%−89.8%CRNon-pCR
73NegPosAnthracycline-based × 616−84.4%−93.8%PRNon-pCR
82PosNegAnthracycline-based × 68−50%−68.8%PRNon-pCR
92NegPosAnthracycline-based × 4, docetaxel × 43.4−61.5%−61.8%PRNon-pCR
103NegNegAnthracycline-based × 66−16.7%−16.7%SDNon-pCR
113PosNegAnthracycline-based × 610−40%−70%PRNon-pCR
122PosNegAnthracycline-based × 65.4−61.1%−64.8%PRNon-pCR
133PosNegAnthracycline-based × 610.9−72.5%−86.2%CRNon-pCR
142PosNegAnthracycline-based × 3, docetaxel × 311.9−65.5%−71%PRNon-pCR
153PosNegAnthracycline-based × 63.20%−43.8%SDNon-pCR
162NegNegAnthracycline-based × 4, docetaxel × 413.2−63.6%−78.8%SDNon-pCR
173NegNegAnthracycline-based × 3, docetaxel × 312−79.2%−90.8%PRNon-pCR
183PosNegAnthracycline-based × 4, docetaxel × 44.1−78%−87.8%PRNon-pCR
193PosNegAnthracycline-based × 612.1−71.1%−91.7%PRpCR
203NegPosAnthracycline-based × 3, docetaxel-trastuzumab × 422−95.5%−95.5%CRpCR
213NegNegAnthracycline-based × 616−70%−87.5%CRpCR
223NegPosAnthracycline-based × 3, docetaxel-trastuzumab × 36.6−50%−66.7%PRpCR
233NegNegAnthracycline-based × 4, docetaxel × 412−25%−81%CRpCR
  • Neg = negative; Pos = positive; PR = partial response; CR = complete response; SD = stable disease.